Medpace Holdings, Inc. Common Stock
MEDPMedpace Holdings, Inc. is a global contract research organization (CRO) that provides comprehensive clinical development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace specializes in conducting clinical trials across various therapeutic areas, offering expertise in regulatory affairs, data management, and project management to support drug development and approval processes.
Company News
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
Medpace, a clinical research organization, saw strong revenue growth and a recovering clinical trial industry, leading to a 13% stock price increase after reporting impressive Q3 earnings with 24% year-over-year revenue growth.
Clinical research organization Medpace reported strong Q3 earnings, beating consensus estimates with $3.86 per share and $659.9 million in revenue, representing a 23.7% year-over-year increase. The company raised fiscal 2025 guidance and saw significant new business awards.
The article compares Surgery Partners (SGRY) and Medpace (MEDP) to determine which is the better value stock. It analyzes various valuation metrics and concludes that SGRY is the superior value option based on its improving earnings outlook and more favorable valuation metrics.
